<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20231116031119&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;ff=20231116031119&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 16 Nov 2023 08:11:22 +0000</lastbuilddate>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Omega-3 Fatty Acids and Atrial Fibrillation: The Importance of the Clinical Question</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968027/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):e207. doi: 10.1016/j.jacc.2023.09.808.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968027/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968027</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.808>10.1016/j.jacc.2023.09.808</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968027</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Frank Qian</dc:creator>
<dc:creator>David Siscovick</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Omega-3 Fatty Acids and Atrial Fibrillation: The Importance of the Clinical Question</dc:title>
<dc:identifier>pmid:37968027</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.808</dc:identifier>
</item>
<item>
<title>Omega-3 Fatty Acids and Atrial Fibrillation: The Difference Between Dietary Consumption and Supplementation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968026/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):e205. doi: 10.1016/j.jacc.2023.08.057.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968026/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968026</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.057>10.1016/j.jacc.2023.08.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968026</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Peder L Myhre</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Omega-3 Fatty Acids and Atrial Fibrillation: The Difference Between Dietary Consumption and Supplementation</dc:title>
<dc:identifier>pmid:37968026</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.057</dc:identifier>
</item>
<item>
<title>Omega-3 Fatty Acids and Atrial Fibrillation Risk: A Controversy Resolved?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968025/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):e203. doi: 10.1016/j.jacc.2023.08.058.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968025/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968025</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.058>10.1016/j.jacc.2023.08.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968025</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Hao Chen</dc:creator>
<dc:creator>Yunan Xu</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Omega-3 Fatty Acids and Atrial Fibrillation Risk: A Controversy Resolved?</dc:title>
<dc:identifier>pmid:37968025</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.058</dc:identifier>
</item>
<item>
<title>Omega 3, Atrial Fibrillation, and Cardiovascular Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968024/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):e201-e202. doi: 10.1016/j.jacc.2023.08.059.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968024/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968024</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.059>10.1016/j.jacc.2023.08.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968024</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Evan L O'Keefe</dc:creator>
<dc:creator>Carl J Lavie</dc:creator>
<dc:creator>Andrew Elagizi</dc:creator>
<dc:creator>Richard V Milani</dc:creator>
<dc:creator>Jari A Laukkanen</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Omega 3, Atrial Fibrillation, and Cardiovascular Outcomes</dc:title>
<dc:identifier>pmid:37968024</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.059</dc:identifier>
</item>
<item>
<title>RESPONSE: Psychological Safety for Cardiology Trainees</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):2066-2067. doi: 10.1016/j.jacc.2023.02.056. Epub 2023 Oct 26.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968023</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.02.056>10.1016/j.jacc.2023.02.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968023</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Margo Vassar</dc:creator>
<dc:creator>Sandra J Lewis</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>RESPONSE: Psychological Safety for Cardiology Trainees</dc:title>
<dc:identifier>pmid:37968023</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.02.056</dc:identifier>
</item>
<item>
<title>Psychological Safety in Cardiovascular Fellowship Training</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):2063-2067. doi: 10.1016/j.jacc.2023.02.055. Epub 2023 Oct 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968022</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.02.055>10.1016/j.jacc.2023.02.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968022</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Vivek T Kulkarni</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Psychological Safety in Cardiovascular Fellowship Training</dc:title>
<dc:identifier>pmid:37968022</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.02.055</dc:identifier>
</item>
<item>
<title>Challenges and Controversies in Peer Review: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>The process of peer review has been the gold standard for evaluating medical science, but significant pressures from the recent COVID-19 pandemic, new methods of communication, larger amounts of research, and an evolving publication landscape have placed significant pressures on this system. A task force convened by the American College of Cardiology identified the 5 most significant controversies associated with the current peer-review process: the effect of preprints, reviewer blinding,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):2054-2062. doi: 10.1016/j.jacc.2023.08.056.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The process of peer review has been the gold standard for evaluating medical science, but significant pressures from the recent COVID-19 pandemic, new methods of communication, larger amounts of research, and an evolving publication landscape have placed significant pressures on this system. A task force convened by the American College of Cardiology identified the 5 most significant controversies associated with the current peer-review process: the effect of preprints, reviewer blinding, reviewer selection, reviewer incentivization, and publication of peer reviewer comments. Although specific solutions to these issues will vary, regardless of how scientific communication evolves, peer review must remain an essential process for ensuring scientific integrity, timely dissemination of information, and better patient care. In medicine, the peer-review process is crucial because harm can occur if poor-quality data or incorrect conclusions are published. With the dramatic increase in scientific publications and new methods of communication, high-quality peer review is more important now than ever.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968021</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.056>10.1016/j.jacc.2023.08.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968021</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Fred M Kusumoto</dc:creator>
<dc:creator>John A Bittl</dc:creator>
<dc:creator>Mark A Creager</dc:creator>
<dc:creator>Harold L Dauerman</dc:creator>
<dc:creator>Anuradha Lala</dc:creator>
<dc:creator>Mary M McDermott</dc:creator>
<dc:creator>Justine Varieur Turco</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Peer Review Task Force of the Scientific Publications Committee</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Challenges and Controversies in Peer Review: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37968021</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.056</dc:identifier>
</item>
<item>
<title>Delineating the Benefits of an Invasive Strategy in Octogenarians With Non-ST-Segment Elevation Acute Coronary Syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):2031-2033. doi: 10.1016/j.jacc.2023.09.810.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968020</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.810>10.1016/j.jacc.2023.09.810</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968020</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>José A Barrabés</dc:creator>
<dc:creator>Eduard Ródenas-Alesina</dc:creator>
<dc:creator>Laia Milà</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Delineating the Benefits of an Invasive Strategy in Octogenarians With Non-ST-Segment Elevation Acute Coronary Syndromes</dc:title>
<dc:identifier>pmid:37968020</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.810</dc:identifier>
</item>
<item>
<title>Long-Term Outcomes of Invasive vs Conservative Strategies for Older Patients With Non-ST-Segment Elevation Acute Coronary Syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients aged ≥80 years with NSTE-ACS, the invasive strategy was superior to the conservative strategy in the reduction of composite events and demonstrated a significant gain in event-free survival. (The After Eighty Study: a randomized controlled trial; NCT01255540).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):2021-2030. doi: 10.1016/j.jacc.2023.09.809.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is a frequent cause of hospital admission in older people, but clinical trials targeting this population are scarce.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The After Eighty Study assessed the effect of an invasive vs a conservative treatment strategy in a very old population with NSTE-ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Between 2010 and 2014, the investigators randomized 457 patients with NSTE-ACS aged ≥80 years (mean age 85 years) to an invasive strategy involving early coronary angiography with immediate evaluation for revascularization and optimal medical therapy or to a conservative strategy (ie, optimal medical therapy). The primary endpoint was a composite of myocardial infarction, need for urgent revascularization, stroke, and death. The long-term outcomes are presented.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: After a median follow up of 5.3 years, the invasive strategy was superior to the conservative strategy in the reduction of the primary endpoint (incidence rate ratio: 0.76; 95% CI: 0.63-0.93; P = 0.0057). The invasive strategy demonstrated a significant gain in event-free survival of 276 days (95% CI: 151-400 days; P = 0.0001) at 5 years and 337 days (95% CI: 123-550 days; P = 0.0001) at 10 years. These results were consistent across subgroups of patients with respect to major cardiovascular prognostic factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients aged ≥80 years with NSTE-ACS, the invasive strategy was superior to the conservative strategy in the reduction of composite events and demonstrated a significant gain in event-free survival. (The After Eighty Study: a randomized controlled trial; NCT01255540).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968019</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.809>10.1016/j.jacc.2023.09.809</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968019</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Erlend S Berg</dc:creator>
<dc:creator>Nicolai K Tegn</dc:creator>
<dc:creator>Michael Abdelnoor</dc:creator>
<dc:creator>Kjetil Røysland</dc:creator>
<dc:creator>Pål Christie Ryalen</dc:creator>
<dc:creator>Lars Aaberge</dc:creator>
<dc:creator>Christian Eek</dc:creator>
<dc:creator>Erik Øie</dc:creator>
<dc:creator>Vibeke Juliebø</dc:creator>
<dc:creator>Erik Gjertsen</dc:creator>
<dc:creator>Anette Hylen Ranhoff</dc:creator>
<dc:creator>Lars Gullestad</dc:creator>
<dc:creator>Njord Nordstrand</dc:creator>
<dc:creator>Bjørn Bendz</dc:creator>
<dc:creator>After Eighty Study Investigators</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Outcomes of Invasive vs Conservative Strategies for Older Patients With Non-ST-Segment Elevation Acute Coronary Syndromes</dc:title>
<dc:identifier>pmid:37968019</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.809</dc:identifier>
</item>
<item>
<title>Sleep, Hypoxia, and Survival in Group 1 Pulmonary Arterial Hypertension: What to Do?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):2006-2008. doi: 10.1016/j.jacc.2023.10.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968018</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.005>10.1016/j.jacc.2023.10.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968018</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Shahrokh Javaheri</dc:creator>
<dc:creator>Virend K Somers</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sleep, Hypoxia, and Survival in Group 1 Pulmonary Arterial Hypertension: What to Do?</dc:title>
<dc:identifier>pmid:37968018</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.005</dc:identifier>
</item>
<item>
<title>Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Sleep-related hypoxia was more strongly associated than AHI with measures of RV dysfunction, death, or transplantation overall and in group 1 non-CTD-associated PAH but only with RV dysfunction in CTD-associated PAH. (Pulmonary Vascular Disease Phenomics Program [PVDOMICS]; NCT02980887).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):1989-2005. doi: 10.1016/j.jacc.2023.09.806.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Group 1 pulmonary arterial hypertension (PAH) is a progressive fatal condition characterized by right ventricular (RV) failure with worse outcomes in connective tissue disease (CTD). Obstructive sleep apnea and sleep-related hypoxia may contribute to RV dysfunction, though the relationship remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to prospectively evaluate the association of the apnea-hypopnea index (AHI) and sleep-related hypoxia with RV function and survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pulmonary Vascular Disease Phenomics (National Heart, Lung, and Blood Institute) cohort participants (patients with group 1 PAH, comparators, and healthy control participants) with sleep studies were included. Multimodal RV functional measures were examined in association with AHI and percentage of recording time with oxygen saturation &lt;90% (T90) per 10-unit increment. Linear models, adjusted for demographics, oxygen, diffusing capacity of the lungs for carbon monoxide, pulmonary hypertension medications, assessed AHI and T90, and RV measures. Log-rank test/Cox proportional hazards models adjusted for demographics, oxygen, and positive airway pressure were constructed for transplantation-free survival analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Analysis included 186 participants with group 1 PAH with a mean age of 52.6 ± 14.1 years; 71.5% were women, 80.8% were Caucasian, and there were 43 events (transplantation or death). AHI and T90 were associated with decreased RV ejection fraction (on magnetic resonance imaging), by 2.18% (-2.18; 95% CI: -4.00 to -0.36; P = 0.019) and 0.93% (-0.93; 95% CI: -1.47 to -0.40; P &lt; 0.001), respectively. T90 was associated with increased RV systolic pressure (on echocardiography), by 2.52 mm Hg (2.52; 95% CI: 1.61 to 3.43; P &lt; 0.001); increased mean pulmonary artery pressure (on right heart catheterization), by 0.27 mm Hg (0.27; 95% CI: 0.05 to 0.49; P = 0.019); and RV hypertrophy (on electrocardiography), 1.24 mm (1.24; 95% CI: 1.10 to 1.40; P &lt; 0.001). T90, but not AHI, was associated with a 17% increased 5-year risk for transplantation or death (HR: 1.17; 95% CI: 1.07 to 1.28). In non-CTD-associated PAH, T90 was associated with a 21% increased risk for transplantation or death (HR: 1.21; 95% CI: 1.08 to 1.34). In CTD-associated PAH, T90 was associated with RV dysfunction, but not death or transplantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sleep-related hypoxia was more strongly associated than AHI with measures of RV dysfunction, death, or transplantation overall and in group 1 non-CTD-associated PAH but only with RV dysfunction in CTD-associated PAH. (Pulmonary Vascular Disease Phenomics Program [PVDOMICS]; NCT02980887).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968017</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.806>10.1016/j.jacc.2023.09.806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968017</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Megan M Lowery</dc:creator>
<dc:creator>Nicholas S Hill</dc:creator>
<dc:creator>Lu Wang</dc:creator>
<dc:creator>Erika B Rosenzweig</dc:creator>
<dc:creator>Aparna Bhat</dc:creator>
<dc:creator>Serpil Erzurum</dc:creator>
<dc:creator>J Emanuel Finet</dc:creator>
<dc:creator>Christine L Jellis</dc:creator>
<dc:creator>Sunjeet Kaur</dc:creator>
<dc:creator>Deborah H Kwon</dc:creator>
<dc:creator>Rawan Nawabit</dc:creator>
<dc:creator>Milena Radeva</dc:creator>
<dc:creator>Gerald J Beck</dc:creator>
<dc:creator>Robert P Frantz</dc:creator>
<dc:creator>Paul M Hassoun</dc:creator>
<dc:creator>Anna R Hemnes</dc:creator>
<dc:creator>Evelyn M Horn</dc:creator>
<dc:creator>Jane A Leopold</dc:creator>
<dc:creator>Franz P Rischard</dc:creator>
<dc:creator>Reena Mehra</dc:creator>
<dc:creator>Pulmonary Vascular Disease Phenomics (PVDOMICS) Study Group</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension</dc:title>
<dc:identifier>pmid:37968017</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.806</dc:identifier>
</item>
<item>
<title>Stress Echocardiography: Another Hilltop, and It Is Better Than Ever</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):1986-1988. doi: 10.1016/j.jacc.2023.09.815.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968016</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.815>10.1016/j.jacc.2023.09.815</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968016</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Wilson Mathias</dc:creator>
<dc:creator>David Costa de Souza Le Bihan</dc:creator>
<dc:creator>Ludhmila Abrahão Hajjar</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Stress Echocardiography: Another Hilltop, and It Is Better Than Ever</dc:title>
<dc:identifier>pmid:37968016</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.815</dc:identifier>
</item>
<item>
<title>Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37968015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Exercise echocardiography of the pulmonary circulation and the right ventricle discloses prognostically relevant differences between healthy subjects, athletes, high-altitude residents, and patients with various cardio-respiratory conditions. (Right Heart International NETwork During Exercise in Different Clinical Conditions; NCT03041337).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 21;82(21):1973-1985. doi: 10.1016/j.jacc.2023.09.807.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exercise echocardiography is used for assessment of pulmonary circulation and right ventricular function, but limits of normal and disease-specific changes remain insufficiently established.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The objective of this study was to explore the physiological vs pathologic response of the right ventricle and pulmonary circulation to exercise.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 2,228 subjects were enrolled: 375 healthy controls, 40 athletes, 516 patients with cardiovascular risk factors, 17 with pulmonary arterial hypertension, 872 with connective tissue diseases without overt pulmonary hypertension, 113 with left-sided heart disease, 30 with lung disease, and 265 with chronic exposure to high altitude. All subjects underwent resting and exercise echocardiography on a semirecumbent cycle ergometer. All-cause mortality was recorded at follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The 5th and 95th percentile of the mean pulmonary artery pressure-cardiac output relationships were 0.2 to 3.5 mm Hg.min/L in healthy subjects without cardiovascular risk factors, and were increased in all patient categories and in high altitude residents. The 5th and 95th percentile of the tricuspid annular plane systolic excursion to systolic pulmonary artery pressure ratio at rest were 0.7 to 2.0 mm/mm Hg at rest and 0.5 to 1.5 mm/mm Hg at peak exercise, and were decreased at rest and exercise in all disease categories and in high-altitude residents. An increased all-cause mortality was predicted by a resting tricuspid annular plane systolic excursion to systolic pulmonary artery pressure &lt;0.7 mm/mm Hg and mean pulmonary artery pressure-cardiac output >;5 mm Hg.min/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Exercise echocardiography of the pulmonary circulation and the right ventricle discloses prognostically relevant differences between healthy subjects, athletes, high-altitude residents, and patients with various cardio-respiratory conditions. (Right Heart International NETwork During Exercise in Different Clinical Conditions; NCT03041337).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37968015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37968015</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.807>10.1016/j.jacc.2023.09.807</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37968015</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Luna Gargani</dc:creator>
<dc:creator>Nicola Riccardo Pugliese</dc:creator>
<dc:creator>Nicolò De Biase</dc:creator>
<dc:creator>Matteo Mazzola</dc:creator>
<dc:creator>Gergely Agoston</dc:creator>
<dc:creator>Michele Arcopinto</dc:creator>
<dc:creator>Paola Argiento</dc:creator>
<dc:creator>William F Armstrong</dc:creator>
<dc:creator>Francesco Bandera</dc:creator>
<dc:creator>Filippo Cademartiri</dc:creator>
<dc:creator>Andreina Carbone</dc:creator>
<dc:creator>Rossana Castaldo</dc:creator>
<dc:creator>Rodolfo Citro</dc:creator>
<dc:creator>Rosangela Cocchia</dc:creator>
<dc:creator>Veronica Codullo</dc:creator>
<dc:creator>Michele D'Alto</dc:creator>
<dc:creator>Antonello D'Andrea</dc:creator>
<dc:creator>Philipp Douschan</dc:creator>
<dc:creator>Iacopo Fabiani</dc:creator>
<dc:creator>Francesco Ferrara</dc:creator>
<dc:creator>Monica Franzese</dc:creator>
<dc:creator>Paolo Frumento</dc:creator>
<dc:creator>Stefano Ghio</dc:creator>
<dc:creator>Ekkehard Grünig</dc:creator>
<dc:creator>Marco Guazzi</dc:creator>
<dc:creator>Jaroslaw D Kasprzak</dc:creator>
<dc:creator>Theodore Kolias</dc:creator>
<dc:creator>Gabor Kovacs</dc:creator>
<dc:creator>André La Gerche</dc:creator>
<dc:creator>Giuseppe Limogelli</dc:creator>
<dc:creator>Alberto Maria Marra</dc:creator>
<dc:creator>Marco Matucci-Cerinic</dc:creator>
<dc:creator>Ciro Mauro</dc:creator>
<dc:creator>Antonella Moreo</dc:creator>
<dc:creator>Lorenza Pratali</dc:creator>
<dc:creator>Brigida Ranieri</dc:creator>
<dc:creator>Salvatore Rega</dc:creator>
<dc:creator>Lawrence Rudski</dc:creator>
<dc:creator>Rajan Saggar</dc:creator>
<dc:creator>Andrea Salzano</dc:creator>
<dc:creator>Walter Serra</dc:creator>
<dc:creator>Anna A Stanziola</dc:creator>
<dc:creator>Mani A Vannan</dc:creator>
<dc:creator>Damien Voilliot</dc:creator>
<dc:creator>Olga Vriz</dc:creator>
<dc:creator>Karina Wierzbowska-Drabik</dc:creator>
<dc:creator>Antonio Cittadini</dc:creator>
<dc:creator>Robert Naeije</dc:creator>
<dc:creator>Eduardo Bossone</dc:creator>
<dc:creator>RIGHT Heart International NETwork (RIGHT-NET) Investigators</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation</dc:title>
<dc:identifier>pmid:37968015</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.807</dc:identifier>
</item>
<item>
<title>Guideline directed medical therapy in patients with heart failure undergoing transcatheter edge-to-edge mitral valve repair: unfulfilled premise</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37967250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 15:ehad678. doi: 10.1093/eurheartj/ehad678. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37967250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37967250</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad678>10.1093/eurheartj/ehad678</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37967250</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Daijiro Tomii</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Guideline directed medical therapy in patients with heart failure undergoing transcatheter edge-to-edge mitral valve repair: unfulfilled premise</dc:title>
<dc:identifier>pmid:37967250</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad678</dc:identifier>
</item>
<item>
<title>Swollen Right Upper Limb in a Man in His 60s Undergoing Hemodialysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966822/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 15. doi: 10.1001/jamacardio.2023.4245. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966822/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37966822</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4245>10.1001/jamacardio.2023.4245</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966822</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Shengmei Liu</dc:creator>
<dc:creator>Sixian Hu</dc:creator>
<dc:creator>Liqing Peng</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Swollen Right Upper Limb in a Man in His 60s Undergoing Hemodialysis</dc:title>
<dc:identifier>pmid:37966822</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4245</dc:identifier>
</item>
<item>
<title>Irregular Rhythm in a Middle-Aged Man Presenting With New-Onset Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 15. doi: 10.1001/jamacardio.2023.4249. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37966819</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4249>10.1001/jamacardio.2023.4249</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966819</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Hussam Ali</dc:creator>
<dc:creator>Ilaria Passarelli</dc:creator>
<dc:creator>Riccardo Cappato</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Irregular Rhythm in a Middle-Aged Man Presenting With New-Onset Heart Failure</dc:title>
<dc:identifier>pmid:37966819</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4249</dc:identifier>
</item>
<item>
<title>Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966817/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 15. doi: 10.1001/jamacardio.2023.4147. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the effect of tafamidis on cardiac function in patients with ATTR-CM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was an exploratory, post hoc analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), a multicenter, international, double-blind, placebo-controlled phase 3 randomized clinical trial conducted from December 2013 to February 2018. The ATTR-ACT included 48 sites in 13 counties and enrolled patients aged 18 to 90 years with ATTR-CM. Data were analyzed from July 2018 to September 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Patients were randomized to tafamidis meglumine, 80 mg or 20 mg, or placebo for 30 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Patients were categorized based on left ventricular (LV) ejection fraction at enrollment as having heart failure with preserved ejection fraction (≥50%), mildly reduced ejection fraction (41% to 49%), or reduced ejection fraction (≤40%). Changes from baseline to month 30 in LV ejection fraction, LV stroke volume, LV global longitudinal strain, and the ratio of early mitral inflow velocity to septal and lateral early diastolic mitral annular velocity (E/e') were compared in patients receiving tafamidis, 80 mg, vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 441 patients were randomized in ATTR-ACT, and 436 patients had available echocardiographic data. Of 436 included patients, 393 (90.1%) were male, and the mean (SD) age was 74 (7) years. A total of 220 (50.5%), 119 (27.3%), and 97 (22.2%) had heart failure with preserved, mildly reduced, and reduced LV ejection fraction, respectively. Over 30 months, there was less pronounced worsening in 4 of the echocardiographic measures in patients receiving tafamidis, 80 mg (n = 176), vs placebo (n = 177) (least squares mean difference: LV stroke volume, 7.02 mL; 95% CI, 2.55-11.49; P = .002; LV global longitudinal strain, -1.02%; 95% CI, -1.73 to -0.31; P = .005; septal E/e', -3.11; 95% CI, -5.50 to -0.72; P = .01; lateral E/e', -2.35; 95% CI, -4.01 to -0.69; P = .006).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Compared with placebo, tafamidis, 80 mg, attenuated the decline of LV systolic and diastolic function over 30 months in patients with ATTR-CM. Approximately half of patients had mildly reduced or reduced LV ejection fraction at enrollment, suggesting that ATTR-CM should be considered as a possible diagnosis in patients with heart failure regardless of underlying LV ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01994889.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966817/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37966817</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4147>10.1001/jamacardio.2023.4147</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966817</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Nowell Fine</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Allan L Klein</dc:creator>
<dc:creator>Fabio Fernandes</dc:creator>
<dc:creator>Neil J Weissman</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Kurt Boman</dc:creator>
<dc:creator>Balarama Gundapaneni</dc:creator>
<dc:creator>Marla B Sultan</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37966817</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4147</dc:identifier>
</item>
<item>
<title>Myocardial infarction caused by in situ thrombosis of a patent foramen ovale assessed by optical coherence tomography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 15:ehad753. doi: 10.1093/eurheartj/ehad753. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37966576</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad753>10.1093/eurheartj/ehad753</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966576</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Wenhao Liu</dc:creator>
<dc:creator>Beibei Song</dc:creator>
<dc:creator>Bo Li</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocardial infarction caused by in situ thrombosis of a patent foramen ovale assessed by optical coherence tomography</dc:title>
<dc:identifier>pmid:37966576</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad753</dc:identifier>
</item>
<item>
<title>Multi-modality imaging diagnosing 'wandering non-coronary Valsalva sinus aneurysm'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966522/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 15:ehad758. doi: 10.1093/eurheartj/ehad758. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966522/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37966522</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad758>10.1093/eurheartj/ehad758</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966522</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Boyu Kong</dc:creator>
<dc:creator>Xin Dong</dc:creator>
<dc:creator>Dianbo Cao</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multi-modality imaging diagnosing 'wandering non-coronary Valsalva sinus aneurysm'</dc:title>
<dc:identifier>pmid:37966522</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad758</dc:identifier>
</item>
<item>
<title>The cardiovascular effects of novel weight loss therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37966486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>The prevalence of overweight and obesity has reached pandemic proportions. Obesity is known to increase the risk for Type 2 diabetes and hypertension, as well as the risk for overt cardiovascular (CV) disease, including myocardial infarction, heart failure, and stroke. The rising prevalence of obesity may counteract the recent advances in primary and secondary prevention of CV disease. Overweight and obesity are common in patients with CV disease; however, cardiologists face several challenges...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 15:ehad664. doi: 10.1093/eurheartj/ehad664. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The prevalence of overweight and obesity has reached pandemic proportions. Obesity is known to increase the risk for Type 2 diabetes and hypertension, as well as the risk for overt cardiovascular (CV) disease, including myocardial infarction, heart failure, and stroke. The rising prevalence of obesity may counteract the recent advances in primary and secondary prevention of CV disease. Overweight and obesity are common in patients with CV disease; however, cardiologists face several challenges in managing body weight in this population. Many may not consider obesity as a therapeutic target probably because there were no previous highly effective and safe pharmacologic interventions to consider. In addition, they may not have the expertise or resources to implement lifestyle interventions and may have limited familiarity with obesity pharmacotherapy. Moreover, the long-term CV effects of obesity pharmacotherapy remain uncertain due to limited CV outcome data with weight loss as the primary intervention. Although current CV guidelines recognize the importance of weight loss, they primarily focus on lifestyle modifications, with fewer details on strategies to utilize obesity pharmacotherapy and surgery. However, the recent 2022 American Diabetes Association/European Association for the Study of Diabetes consensus on the management of Type 2 diabetes has moved up weight management to the front of the treatment algorithm, by prioritizing the use of pharmacologic interventions such as glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, which have potent weight-lowering effects, in addition to glucose-lowering effects. This review appraises the current evidence regarding the CV effects of weight-loss interventions. Considering this evidence, practical guidance is provided to assist cardiologists in developing and implementing treatment plans, which may allow optimal weight management while maximizing CV benefits and minimizing side effects to improve the overall well-being of people with CV disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37966486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37966486</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad664>10.1093/eurheartj/ehad664</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37966486</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Muhammad Shariq Usman</dc:creator>
<dc:creator>Melanie Davies</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Julio Rosenstock</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The cardiovascular effects of novel weight loss therapies</dc:title>
<dc:identifier>pmid:37966486</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad664</dc:identifier>
</item>
<item>
<title>Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37965787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231116031119&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These findings identify SDR proteins as important regulators of mitochondrial function and molecular targets of NAD^(+)-based therapy. Furthermore, the benefit is observed regardless of Sirt3-mediated mitochondrial protein deacetylation, a widely held mechanism for NAD^(+)-based therapy for heart failure. The data also show that NAD^(+)-based therapy can be useful in pre-existing heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.066039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Strategies to increase cellular NAD<sup>+</sup> (oxidized nicotinamide adenine dinucleotide) level have prevented cardiac dysfunction in multiple models of heart failure, but molecular mechanisms remain unclear. Little is known about the benefits of NAD<sup>+</sup>-based therapies in failing hearts after the symptoms of heart failure have appeared. Most pretreatment regimens suggested mechanisms involving activation of sirtuin, especially Sirt3 (sirtuin 3), and mitochondrial protein acetylation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We induced cardiac dysfunction by pressure overload in SIRT3-deficient (knockout) mice and compared their response with nicotinamide riboside chloride treatment with wild-type mice. To model a therapeutic approach, we initiated the treatment in mice with established cardiac dysfunction and found nicotinamide riboside chloride improved mitochondrial function and blunted heart failure progression. Similar benefits were observed in wild-type and knockout mice. Boosting NAD<sup>+</sup> level improved the function of NAD(H) redox-sensitive SDR (short-chain dehydrogenase/reductase) family proteins. Upregulation of Mrpp2 (mitochondrial ribonuclease P protein 2), a multifunctional SDR protein and a subunit of mitochondrial ribonuclease P, improves mitochondrial DNA transcripts processing and electron transport chain function. Activation of SDRs in the retinol metabolism pathway stimulates RXRα (retinoid X receptor α)/PPARα (proliferator-activated receptor α) signaling and restores mitochondrial oxidative metabolism. Downregulation of Mrpp2 and impaired mitochondrial ribonuclease P were found in human failing hearts, suggesting a shared mechanism of defective mitochondrial biogenesis in mouse and human heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify SDR proteins as important regulators of mitochondrial function and molecular targets of NAD<sup>+</sup>-based therapy. Furthermore, the benefit is observed regardless of Sirt3-mediated mitochondrial protein deacetylation, a widely held mechanism for NAD<sup>+</sup>-based therapy for heart failure. The data also show that NAD<sup>+</sup>-based therapy can be useful in pre-existing heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37965787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231116031119&v=2.17.9.post6+86293ac">37965787</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066039>10.1161/CIRCULATIONAHA.123.066039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37965787</guid>
<pubDate>Wed, 15 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Matthew A Walker</dc:creator>
<dc:creator>Hongye Chen</dc:creator>
<dc:creator>Aprajita Yadav</dc:creator>
<dc:creator>Julia Ritterhoff</dc:creator>
<dc:creator>Outi Villet</dc:creator>
<dc:creator>Tim McMillen</dc:creator>
<dc:creator>Yuliang Wang</dc:creator>
<dc:creator>Hayley Purcell</dc:creator>
<dc:creator>Danijel Djukovic</dc:creator>
<dc:creator>Daniel Raftery</dc:creator>
<dc:creator>Nina Isoherranen</dc:creator>
<dc:creator>Rong Tian</dc:creator>
<dc:date>2023-11-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation</dc:title>
<dc:identifier>pmid:37965787</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066039</dc:identifier>
</item>





























</channel>
</rss>